

How to Read the FoundationOne[™] Report

THE FIRST PAGE OF THE REPORT SHOWS the patient and ordering physicians information...

The genomic alterations identified in the hundreds of genes assayed...

The targeted therapies that may be relevant based on those genomic alterations both in the patients tumor type and in other tumor types...

and whether there are relevant clinical trials.

FOUNDATIONONE		Vanit form			
Wilmet .			Later Little Diric Direct Little Little		1511
NOVY THE TEST		-			the state of the state
PATIENT RESULTS			TUMOR TYPE: LUNG ADDIOCARCINOMA		
4 Peorgana associated and generated difficul bounds 3 December Association with links of response 4 contrast Dece			Decement Anti-retrieve Streenfeart EXIPIT-1077-1972-0477 CCR01 serverification Asticina Colory Additional Decement Adversion Streether 10363 The Longentum Colory and Streether 10363		
THERAPEUTIC	MPLICATION		Teaters	to if he good mean	C preser of a 10 M Agentia
	TOA App			Purspins article	
EOFR NTL PTOAT			damiate		
	Paren-	19	100		ra, keek pitrologi triangi. enform
			Sec.		

Genomic Alterations Detected	FDA Approved Therapies (in patient's tumor type)	FDA Approved Therapies (in another tumor type)	Potential Clinical Trials Yes, see clinical trials section Yes, see clinical trials section None
EGFR N771_P772>KFP	Erlotinib Gefitinib	Cetuximab Panitumumab	
CCND1 amplification	None	None	
ARID1A Q633*	None	None	



<text><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header>

The second page of the report
contains a more detailedThe Therapies section of the
report provides more detailsinterpretive statement that
references the frequency of
the genomic alteration, itson approved therapies to which
the patient's cancer may be
sensitive or resistant based on
its genomic profile.

<section-header><section-header><text><text><section-header><section-header><section-header>

The clinical trials section of the report provides some detail on currently available clinical trials for which the patient may be eligible based on genomic profile of the patient's cancer. This section also provides guidance to the physician to help identify other trials in publicly available databases for which the patient may be eligible.



The appendix of the report contains the full list of genes assayed in the test so you can see all the genes in which there were no alterations found. The appendix also lists the references used in creating the report and technical notes about the test.